Skip Navigation



Journal of the National Cancer Institute Advance Access published online on January 8, 2008
JNCI Journal of the National Cancer Institute, doi:10.1093/jnci/djm305
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/2/81    most recent
djm305v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Narazaki, M.
Right arrow Articles by Tosato, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Narazaki, M.
Right arrow Articles by Tosato, G.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press 2008.

EDITORIALS

Neuropilin-2: A New Molecular Target for Antiangiogenic and Antitumor Strategies

Masashi Narazaki, Marta Segarra, Giovanna Tosato

Affiliations of authors: Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD (MS, GT); Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka Japan (MN)

Correspondence to: Giovanna Tosato, MD, Laboratory of Cellular Oncology, Center for Cancer Research, Bldg 37, Rm 4124, National Cancer Institute, Bethesda, MD 20892 (e-mail: tosatog@mail.nih.gov).

The first 10% of the full text of this article appears below.

Aggressive cancers grow progressively, invade locally, and metastasize through a multistep process that involves a malignant cell and a supportive environment (1). Tumor neovascularization critically contributes to tumor growth (2). Hence, there has been great interest in reducing cancer progression by shutting down the tumor blood supply (3). The antiangiogenic drugs currently approved for cancer treatment include bevacizumab (Avastin), a humanized monoclonal antibody blocking vascular endothelial growth factor (VEGF), and sorafenib (Nexavar) and sunitinib (Sutent), synthetic inhibitors of VEGF receptor signaling (4,5). These VEGF-targeted therapies have shown benefit in certain cancer types, but responses have generally been modest and measured in months of extended cancer survival (6–8). This experience . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Therapeutic Targeting of Neuropilin-2 on Colorectal Carcinoma Cells Implanted in the Murine Liver
Michael J. Gray, George Van Buren, Nikolaos A. Dallas, Ling Xia, Xuemei Wang, Anthony D. Yang, Ray J. Somcio, Yvonne G. Lin, Sherry Lim, Fan Fan, Lingegowda S. Mangala, Thiruvengadam Arumugam, Craig D. Logsdon, Gabriel Lopez-Berestein, Anil K. Sood, and Lee M. Ellis
J Natl Cancer Inst 2008 100: 109-120. [Abstract] [Full Text] [PDF]

IN THIS ISSUE
J Natl Cancer Inst 2008 100: 79. [Extract] [Full Text] [PDF]